Olga V. Guzun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Olga V. Guzun has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Oleg Zadorozhnyy
Department of Biological Effects and Laser Applications, The Filatov Institute of Eye Diseases and Tissue Therapy of NAMS of Ukraine, Odesa
12 shared publications - Natalia V. Konovalova
Odesa National Medical University, Odesa, Ukraine
11 shared publications - Vladimir Vychuzhanin
Odesа Polytechnic National University
6 shared publications - Andrii R. Korol
Division of Research of Laser Biologic Action and Application in Ophthalmology, State Institution "THE Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine", Odesa, Ukraine
5 shared publications - Liudmyla Velychko
State Institution “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine
4 shared publications - N. I. Khramenko
State Institution “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa, Ukraine
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Ukrainian Society of Ophthalmologists in Ukrainian Journal of Ophthalmology
- No. 5,p. 13-22
Cumulative Thermal Accumulation in Transscleral Cyclophotocoagulation: Mathematical Modeling of Controlled Versus Destructive Thermal Effects in Secondary Neovascular Glaucoma
Purpose. To quantitatively characterize the cumulative thermal dynamics of ciliary body tissue during serial transscleral cyclophotocoagulation and to evaluate the potential applicability of the thermal accumulation index (TAI) as a tool for predicting controlled coagulative and potentially destructive thermal effects in secondary neovascular glaucoma. Methods. Stepwise mathematical modeling of serial transscleral cyclophotocoagulation (20 applications of 2 s with 1 s inter-application intervals) was performed. For each cycle, initial tissue temperature (Tstart), maximum temperature (Tmax), temperature rise (ΔT), and inter-application heat loss (HeatLoss) were determined. Total time within coagulative (50–60 °C) and destructive (>60 °C) temperature ranges, as well as the area under the temperature curve within the coagulative range (AUTC), were assessed. The thermal accumulation index (TAI) was calculated as the mean increase of the initial temperature above the baseline level of 37 °C. Additional threshold and scenario analyses were performed by varying laser exposure parameters. Results. Serial laser exposure produced cumulative thermal dynamics characterized by gradual elevation of baseline tissue temperature from 37.0 °C to 42.7 °C. The cumulative temperature increase reached 57.0 °C, corresponding to TAI = 2.85 °C and indicating controlled thermal accumulation without transition to the destructive temperature range. Analysis of thermal profiles demonstrated that shorter inter-application intervals or higher energy delivery enhanced thermal accumulation. Within the mathematical model, TAI values exceeding 4.0 °C were associated with an increased risk of tissue overheating and transition to the destructive temperature range (>60 °C). Under simulated conditions, the continuous-wave 1 W mode corresponded to a profile of controlled low-power coagulation. Conclusions. Cumulative thermal accumulation represents an important component of tissue temperature response during serial TSCPC and is determined by incomplete cooling between consecutive applications. The proposed TAI enables quantitative characterization of inter-application heat accumulation and may be considered an integral indicator of cumulative thermal dynamics under different laser exposure regimes. Under simulated conditions, the low-power continuous-wave 1 W mode provided a controlled coagulative effect without transition to the destructive temperature range, consistent with the low-dose / slow coagulation concept. The obtained findings are model-based and require further experimental and clinical validation.
- 1 October 2026
- Published by Ukrainian Society of Ophthalmologists in Ukrainian Journal of Ophthalmology
- No. 5,p. 13-22
Open AccessCumulative Thermal Accumulation in Transscleral Cyclophotocoagulation: Mathematical Modeling of Controlled Versus Destructive Thermal Effects in Secondary Neovascular Glaucoma
Purpose. To quantitatively characterize the cumulative thermal dynamics of ciliary body tissue during serial transscleral cyclophotocoagulation and to evaluate the potential applicability of the thermal accumulation index (TAI) as a tool for predicting controlled coagulative and potentially destructive thermal effects in secondary neovascular glaucoma. Methods. Stepwise mathematical modeling of serial transscleral cyclophotocoagulation (20 applications of 2 s with 1 s inter-application intervals) was performed. For each cycle, initial tissue temperature (Tstart), maximum temperature (Tmax), temperature rise (ΔT), and inter-application heat loss (HeatLoss) were determined. Total time within coagulative (50–60 °C) and destructive (>60 °C) temperature ranges, as well as the area under the temperature curve within the coagulative range (AUTC), were assessed. The thermal accumulation index (TAI) was calculated as the mean increase of the initial temperature above the baseline level of 37 °C. Additional threshold and scenario analyses were performed by varying laser exposure parameters. Results. Serial laser exposure produced cumulative thermal dynamics characterized by gradual elevation of baseline tissue temperature from 37.0 °C to 42.7 °C. The cumulative temperature increase reached 57.0 °C, corresponding to TAI = 2.85 °C and indicating controlled thermal accumulation without transition to the destructive temperature range. Analysis of thermal profiles demonstrated that shorter inter-application intervals or higher energy delivery enhanced thermal accumulation. Within the mathematical model, TAI values exceeding 4.0 °C were associated with an increased risk of tissue overheating and transition to the destructive temperature range (>60 °C). Under simulated conditions, the continuous-wave 1 W mode corresponded to a profile of controlled low-power coagulation. Conclusions. Cumulative thermal accumulation represents an important component of tissue temperature response during serial TSCPC and is determined by incomplete cooling between consecutive applications. The proposed TAI enables quantitative characterization of inter-application heat accumulation and may be considered an integral indicator of cumulative thermal dynamics under different laser exposure regimes. Under simulated conditions, the low-power continuous-wave 1 W mode provided a controlled coagulative effect without transition to the destructive temperature range, consistent with the low-dose / slow coagulation concept. The obtained findings are model-based and require further experimental and clinical validation.
- Open Access
- 30 September 2026
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 22 (3) , 164-175
Pathogenesis of secondary neovascular glaucoma: The role of ischaemia, systemic inflammation, and microcirculation
Relevance. The high clinical heterogeneity of the course of neovascular glaucoma and insufficient effectiveness of assessing its progression only according to conventional clinical criteria necessitate a comprehensive analysis of the ischaemic, inflammatory, and microcirculatory mechanisms of pathogenesis. Aim. To summarise current ideas about the pathogenesis of neovascular glaucoma and substantiate the integral ischaemic-inflammatory-microcirculatory model of its development based on the analysis of literature sources and the results of clinical studies. Materials and methods. A narrative review of current scientific literature was conducted in accordance with PRISMA 2020 approaches on the role of ischaemia, angiogenesis, systemic inflammation, and microcirculation in the pathogenesis of neovascular glaucoma. In addition, clinical data were analysed, including intraocular pressure, best-corrected visual acuity, the degree of neovascularisation according to the Weiss classification, integral inflammatory indices (SII, SIRI, AISI), a marker of endothelial activation (ICAM-1/CD54), an apoptosis marker (CD95/Fas), and a microcirculatory parameter (RQ). Results. It has been shown that neovascular glaucoma develops as a result of the interaction between retinal ischaemia, pathological angiogenesis, systemic inflammation, and microcirculatory disturbances. The association of integral inflammatory indices, a marker of endothelial activation, and apoptosis-associated signalling with the severity of the disease was established. Heterogeneity of microcirculatory changes and a nonlinear (U-shaped) relationship between RQ score and clinical outcomes were found, reflecting different variants of perfusion disorders. It has been demonstrated that the integration of clinical, biomarker, and haemodynamic parameters provides a more accurate assessment of disease severity compared to conventional criteria. Conclusions. Neovascular glaucoma is a heterogeneous disease in the pathogenesis of which the ischaemic-inflammatory-microcirculatory model plays a key role. An integrated approach to patient assessment sets the stage for clinical and biological risk stratification and the introduction of personalised pathogenetically oriented treatment strategies. Practical significance. Integration of clinical, inflammatory, and haemodynamic parameters can improve the accuracy of assessing the biological activity of secondary neovascular glaucoma, risk stratification, and rationale for personalised treatment tactics.
- 30 September 2026
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 22 (3) , 164-175
Open AccessPathogenesis of secondary neovascular glaucoma: The role of ischaemia, systemic inflammation, and microcirculation
Relevance. The high clinical heterogeneity of the course of neovascular glaucoma and insufficient effectiveness of assessing its progression only according to conventional clinical criteria necessitate a comprehensive analysis of the ischaemic, inflammatory, and microcirculatory mechanisms of pathogenesis. Aim. To summarise current ideas about the pathogenesis of neovascular glaucoma and substantiate the integral ischaemic-inflammatory-microcirculatory model of its development based on the analysis of literature sources and the results of clinical studies. Materials and methods. A narrative review of current scientific literature was conducted in accordance with PRISMA 2020 approaches on the role of ischaemia, angiogenesis, systemic inflammation, and microcirculation in the pathogenesis of neovascular glaucoma. In addition, clinical data were analysed, including intraocular pressure, best-corrected visual acuity, the degree of neovascularisation according to the Weiss classification, integral inflammatory indices (SII, SIRI, AISI), a marker of endothelial activation (ICAM-1/CD54), an apoptosis marker (CD95/Fas), and a microcirculatory parameter (RQ). Results. It has been shown that neovascular glaucoma develops as a result of the interaction between retinal ischaemia, pathological angiogenesis, systemic inflammation, and microcirculatory disturbances. The association of integral inflammatory indices, a marker of endothelial activation, and apoptosis-associated signalling with the severity of the disease was established. Heterogeneity of microcirculatory changes and a nonlinear (U-shaped) relationship between RQ score and clinical outcomes were found, reflecting different variants of perfusion disorders. It has been demonstrated that the integration of clinical, biomarker, and haemodynamic parameters provides a more accurate assessment of disease severity compared to conventional criteria. Conclusions. Neovascular glaucoma is a heterogeneous disease in the pathogenesis of which the ischaemic-inflammatory-microcirculatory model plays a key role. An integrated approach to patient assessment sets the stage for clinical and biological risk stratification and the introduction of personalised pathogenetically oriented treatment strategies. Practical significance. Integration of clinical, inflammatory, and haemodynamic parameters can improve the accuracy of assessing the biological activity of secondary neovascular glaucoma, risk stratification, and rationale for personalised treatment tactics.
- Open Access
- 30 September 2026
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 32 (3) , 93-101
Neovascular glaucoma as a chronic neuroischemic optic neuropathy: the impact of cumulative burden on vision-related quality of life in a 36-month prospective study
Purpose. To evaluate the impact of treatment burden as a functional marker of chronic neuroischemic optic neuropathy progression on vision-related quality of life in patients with neovascular glaucoma. Methods. This prospective cohort study included 351 patients (351 eyes) with secondary neovascular glaucoma associated with proliferative diabetic retinopathy or retinal vein occlusion. Patients were followed for 36 months. Vision-related quality of life was assessed using the validated NEI VFQ-25 questionnaire at baseline, 12 months, and 36 months. Cumulative Burden Index (CBI) was defined as a composite cumulative measure incorporating both treatment intensity (number of transscleral cyclophotocoagulation (TSCPC) procedures) and disease-related burden (severity of complications present at baseline and during follow-up). Statistical analysis included descriptive statistics, linear and logistic regression, ROC analysis, and multilayer perceptron (MLP) neural network modeling. Results. Patients with successful treatment outcomes (n = 282; 80.3%) demonstrated improvement in vision-related quality of life (ΔQoL = +10.26 ± 6.18), whereas patients with resistant disease (n = 69; 19.7%) showed significant deterioration (ΔQoL = −7.43 ± 6.97; p < 0.001). Higher CBI values were independently associated with lower NEI VFQ-25 scores (β = −1.78; 95% CI −2.57 to −0.99; p < 0.001). The between-group difference corresponded to a very large clinical effect size (Cohen’s d = 2.77). In the logistic regression model, CBI remained an independent predictor of unfavorable treatment outcome (OR = 0.48; 95% CI 0.34–0.68; p < 0.001). The neural network model demonstrated good discriminative performance for outcome prediction (AUC = 0.83; 95% CI 0.78–0.88). Conclusions. The CBI was independently associated with vision-related quality of life in patients with neovascular glaucoma and may serve as an integrated marker of chronic neurovascular disease burden. Increased CBI values were associated with significant functional impairment and a poorer clinical prognosis. Integration of composite clinical indices with machine learning approaches may improve risk stratification, personalized treatment planning, and digital clinical decision support in patients with neovascular glaucoma.
- 30 September 2026
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 32 (3) , 93-101
Open AccessNeovascular glaucoma as a chronic neuroischemic optic neuropathy: the impact of cumulative burden on vision-related quality of life in a 36-month prospective study
Purpose. To evaluate the impact of treatment burden as a functional marker of chronic neuroischemic optic neuropathy progression on vision-related quality of life in patients with neovascular glaucoma. Methods. This prospective cohort study included 351 patients (351 eyes) with secondary neovascular glaucoma associated with proliferative diabetic retinopathy or retinal vein occlusion. Patients were followed for 36 months. Vision-related quality of life was assessed using the validated NEI VFQ-25 questionnaire at baseline, 12 months, and 36 months. Cumulative Burden Index (CBI) was defined as a composite cumulative measure incorporating both treatment intensity (number of transscleral cyclophotocoagulation (TSCPC) procedures) and disease-related burden (severity of complications present at baseline and during follow-up). Statistical analysis included descriptive statistics, linear and logistic regression, ROC analysis, and multilayer perceptron (MLP) neural network modeling. Results. Patients with successful treatment outcomes (n = 282; 80.3%) demonstrated improvement in vision-related quality of life (ΔQoL = +10.26 ± 6.18), whereas patients with resistant disease (n = 69; 19.7%) showed significant deterioration (ΔQoL = −7.43 ± 6.97; p < 0.001). Higher CBI values were independently associated with lower NEI VFQ-25 scores (β = −1.78; 95% CI −2.57 to −0.99; p < 0.001). The between-group difference corresponded to a very large clinical effect size (Cohen’s d = 2.77). In the logistic regression model, CBI remained an independent predictor of unfavorable treatment outcome (OR = 0.48; 95% CI 0.34–0.68; p < 0.001). The neural network model demonstrated good discriminative performance for outcome prediction (AUC = 0.83; 95% CI 0.78–0.88). Conclusions. The CBI was independently associated with vision-related quality of life in patients with neovascular glaucoma and may serve as an integrated marker of chronic neurovascular disease burden. Increased CBI values were associated with significant functional impairment and a poorer clinical prognosis. Integration of composite clinical indices with machine learning approaches may improve risk stratification, personalized treatment planning, and digital clinical decision support in patients with neovascular glaucoma.
- Open Access
- 1 August 2026
- Published by Ukrainian Society of Ophthalmologists
- No. 4,p. 4-13
Selective transscleral cyclophotocoagulation: mathematical modeling for evaluating the efficacy-safety balance in neovascular glaucoma
Purpose. To quantitatively evaluate the efficacy-safety balance of transscleral cyclophotocoagulation (TSCPC) through a mathematical modeling-based analysis of thermal tissue response in the ciliary body, and to determine the laser exposure parameters for achieving a selective coagulation effect in neovascular glaucoma (NVG). Material and Methods. A model of heat transfer in the ciliary body was developed using the Pennes bioheat transfer equation. Continuous Wave (CW) TSCPC and MicroPulse TSCPC at 1 W and 2W for a single 2-s application and a series of 2-s applications were subjected to analysis. The following parameters were determined: maximum temperature (Tmax), time to reach 50 °C (t50), time in the temperature range 50–60 °C (t50-60), and time in the temperature range above 60 °C (t(>60)). Integral thermal indices including the Therapeutic Exposure Index (TEI), Destructive Exposure Index (DEI), and Thermal Selectivity Index (TSI), and Safety Margin were calculated. Results. A single 2-s CW-TSCPC application at 1 W enabled achieving the coagulation temperature threshold (Tmax = 50.8 °C; t50 = 1.44 s) without a transition to the destructive temperature range (> 60 °C), whereas that at 2 W was accompanied by tissue overheating (Tmax = 61.8 °C; t50 = 0.4 s). A series of 2-s CW laser applications at 1 W enabled accumulation of the heat dose within the therapeutic window (t50–60 = 17.1 s; DEI = 0), whereas that at 2 W resulted in large t(>60) values (t(>60) = 39.7 s; DEI = 0.67). MicroPulse TSCPC did not result in reaching the coagulation threshold (Tmax ≤ 49 °C). The integral indices confirmed the optimal efficacy–safety balance for a CW-TSCPC application at 1 W. Conclusion. The 60 °C temperature threshold determines the transition from coagulative to destructive tissue injury. Therefore, CW-TSCPC at 1 W provides an optimal efficacy-safety balance due to a selective coagulative effect, and can be considered a pathophysiologically justified strategy for optimizing TSCPC parameters in NVG.
- 1 August 2026
- Published by Ukrainian Society of Ophthalmologists
- No. 4,p. 4-13
Open AccessSelective transscleral cyclophotocoagulation: mathematical modeling for evaluating the efficacy-safety balance in neovascular glaucoma
Purpose. To quantitatively evaluate the efficacy-safety balance of transscleral cyclophotocoagulation (TSCPC) through a mathematical modeling-based analysis of thermal tissue response in the ciliary body, and to determine the laser exposure parameters for achieving a selective coagulation effect in neovascular glaucoma (NVG). Material and Methods. A model of heat transfer in the ciliary body was developed using the Pennes bioheat transfer equation. Continuous Wave (CW) TSCPC and MicroPulse TSCPC at 1 W and 2W for a single 2-s application and a series of 2-s applications were subjected to analysis. The following parameters were determined: maximum temperature (Tmax), time to reach 50 °C (t50), time in the temperature range 50–60 °C (t50-60), and time in the temperature range above 60 °C (t(>60)). Integral thermal indices including the Therapeutic Exposure Index (TEI), Destructive Exposure Index (DEI), and Thermal Selectivity Index (TSI), and Safety Margin were calculated. Results. A single 2-s CW-TSCPC application at 1 W enabled achieving the coagulation temperature threshold (Tmax = 50.8 °C; t50 = 1.44 s) without a transition to the destructive temperature range (> 60 °C), whereas that at 2 W was accompanied by tissue overheating (Tmax = 61.8 °C; t50 = 0.4 s). A series of 2-s CW laser applications at 1 W enabled accumulation of the heat dose within the therapeutic window (t50–60 = 17.1 s; DEI = 0), whereas that at 2 W resulted in large t(>60) values (t(>60) = 39.7 s; DEI = 0.67). MicroPulse TSCPC did not result in reaching the coagulation threshold (Tmax ≤ 49 °C). The integral indices confirmed the optimal efficacy–safety balance for a CW-TSCPC application at 1 W. Conclusion. The 60 °C temperature threshold determines the transition from coagulative to destructive tissue injury. Therefore, CW-TSCPC at 1 W provides an optimal efficacy-safety balance due to a selective coagulative effect, and can be considered a pathophysiologically justified strategy for optimizing TSCPC parameters in NVG.
- Open Access
- 30 June 2026
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 22 (2) , 14-23
Systemic biomarkers of apoptosis and endothelial activation in the pathogenesis of rubeosis iridis and iridocorneal angle neovascularisation in secondary neovascular glaucoma
Aim. To assess systemic levels of CD95 (Fas) and ICAM-1 (CD54) in patients with secondary neovascular glaucoma (NVG), to determine the relationship with the severity of iris rubeosis and the iridocorneal angle, and to evaluate the role of endothelial apoptosis in neovascular remodelling of the anterior segment of the eye. Materials and methods. A single-centre cross-sectional study included 186 eyes with secondary NVG (96 associated with proliferative diabetic retinopathy and 90 following retinal vein occlusion) and 34 eyes in the control group. The severity of rubeosis was assessed using the Weiss grading scale. CD95 and ICAM-1 levels in peripheral blood were measured using an immunocytochemical method. Results. In patients with NVG, CD95 and ICAM-1 levels were significantly higher compared with controls (p < 0.001). Both markers positively correlated with the severity of rubeosis according to Weiss (CD95: rs = 0.46; ICAM-1: rs = 0.45; p < 0.001) and with intraocular pressure. In a multivariable ordinal logistic regression model, CD95 and ICAM-1 remained independently associated with more severe rubeosis after adjustment for aetiology and intraocular pressure (CD95: OR = 2.31; 95% CI 1.27-4.18; p = 0.006; ICAM-1: OR = 2.48; 95% CI 1.56-3.95; p < 0.001). ROC analysis demonstrated moderate discriminative ability of the markers for detecting clinically significant rubeosis (Weiss ≥ II): AUC = 0.729 for CD95 and AUC = 0.730 for ICAM-1. Cut-off values were 687 cells/µL and 542 cells/µL, respectively. Conclusions. CD95 (Fas) and ICAM-1 (CD54) are associated with the severity of rubeosis in secondary NVG and may serve as systemic biomarkers for neovascular remodelling and risk stratification of disease progression.
- 30 June 2026
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 22 (2) , 14-23
Open AccessSystemic biomarkers of apoptosis and endothelial activation in the pathogenesis of rubeosis iridis and iridocorneal angle neovascularisation in secondary neovascular glaucoma
Aim. To assess systemic levels of CD95 (Fas) and ICAM-1 (CD54) in patients with secondary neovascular glaucoma (NVG), to determine the relationship with the severity of iris rubeosis and the iridocorneal angle, and to evaluate the role of endothelial apoptosis in neovascular remodelling of the anterior segment of the eye. Materials and methods. A single-centre cross-sectional study included 186 eyes with secondary NVG (96 associated with proliferative diabetic retinopathy and 90 following retinal vein occlusion) and 34 eyes in the control group. The severity of rubeosis was assessed using the Weiss grading scale. CD95 and ICAM-1 levels in peripheral blood were measured using an immunocytochemical method. Results. In patients with NVG, CD95 and ICAM-1 levels were significantly higher compared with controls (p < 0.001). Both markers positively correlated with the severity of rubeosis according to Weiss (CD95: rs = 0.46; ICAM-1: rs = 0.45; p < 0.001) and with intraocular pressure. In a multivariable ordinal logistic regression model, CD95 and ICAM-1 remained independently associated with more severe rubeosis after adjustment for aetiology and intraocular pressure (CD95: OR = 2.31; 95% CI 1.27-4.18; p = 0.006; ICAM-1: OR = 2.48; 95% CI 1.56-3.95; p < 0.001). ROC analysis demonstrated moderate discriminative ability of the markers for detecting clinically significant rubeosis (Weiss ≥ II): AUC = 0.729 for CD95 and AUC = 0.730 for ICAM-1. Cut-off values were 687 cells/µL and 542 cells/µL, respectively. Conclusions. CD95 (Fas) and ICAM-1 (CD54) are associated with the severity of rubeosis in secondary NVG and may serve as systemic biomarkers for neovascular remodelling and risk stratification of disease progression.
- Open Access
- 29 June 2026
- Published by Ukrainian Society of Ophthalmologists in Ukrainian Journal of Ophthalmology
- No. 3,p. 22-30
Симпато-адреналова дисрегуляція та клінічні прояви ангіогенної активності при вторинній неоваскулярній глаукомі
Мета. Дослідити взаємозв’язок між β - адренорецепторною активністю як маркером симпато-адреналової дисрегуляції та клінічними проявами ангіогенної активності у пацієнтів із вторинною неоваскулярною глаукомою.Матеріал та методи. У проспективне обсерваційне дослідження включено 188 пацієнтів із вторинною неоваскулярною глаукомою (112 – на тлі проліферативної діабетичної ретинопатії та 76 – внаслідок оклюзії вен сітківки) та 34 особи контрольної групи. Усім учасникам виконували стандартне офтальмологічне обстеження з оцінкою ступеня рубеозу райдужки за класифікацією Weiss. β-адренорецепторну активність (β-AR) визначали за методикою оцінки специфічної чутливості лімфоцитів до адреналіну. Для статистичного аналізу використовували непараметричні методи, кореляційний аналіз Спірмена, ROC-аналіз та логістичну регресію.Результати. Рівень β-AR activity був достовірно вищим у пацієнтів із неоваскулярною глаукомою порівняно з контрольною групою та перевищував контрольні значення у 1,7–2,0 рази (p < 0,05). Встановлено сильний позитивний кореляційний зв’язок між β-AR activity та ступенем рубеозу райдужки за Weiss (rs=0,69; p<0,001). ROC-аналіз продемонстрував помірну дискримінаційну здатність β-AR activity щодо виявлення клінічно значущого рубеозу райдужки (Weiss ≥ 2) (AUC = 0,70). При пороговому значенні β-AR activity ≥ 14 ризик клінічно значущої неоваскуляризації райдужки зростав у 5,0 разів (OR = 5,02; 95% ДІ 2,64–9,56; p < 0,001).Висновки. Вторинна неоваскулярна глаукома асоціюється з підвищенням β-адренорецепторної активності, що може відображати залучення симпато-адреналової дисрегуляції до перебігу захворювання. Виявлений зв’язок між β-AR activity та вираженістю рубеозу райдужки свідчить про асоціацію системних нейровегетативних механізмів із клінічними проявами ангіогенної активності. β-AR може розглядатися як перспективний фенотип-визначальний маркер клінічної активності неоваскулярної глаукоми.
- 29 June 2026
- Published by Ukrainian Society of Ophthalmologists in Ukrainian Journal of Ophthalmology
- No. 3,p. 22-30
Open AccessСимпато-адреналова дисрегуляція та клінічні прояви ангіогенної активності при вторинній неоваскулярній глаукомі
Мета. Дослідити взаємозв’язок між β - адренорецепторною активністю як маркером симпато-адреналової дисрегуляції та клінічними проявами ангіогенної активності у пацієнтів із вторинною неоваскулярною глаукомою.Матеріал та методи. У проспективне обсерваційне дослідження включено 188 пацієнтів із вторинною неоваскулярною глаукомою (112 – на тлі проліферативної діабетичної ретинопатії та 76 – внаслідок оклюзії вен сітківки) та 34 особи контрольної групи. Усім учасникам виконували стандартне офтальмологічне обстеження з оцінкою ступеня рубеозу райдужки за класифікацією Weiss. β-адренорецепторну активність (β-AR) визначали за методикою оцінки специфічної чутливості лімфоцитів до адреналіну. Для статистичного аналізу використовували непараметричні методи, кореляційний аналіз Спірмена, ROC-аналіз та логістичну регресію.Результати. Рівень β-AR activity був достовірно вищим у пацієнтів із неоваскулярною глаукомою порівняно з контрольною групою та перевищував контрольні значення у 1,7–2,0 рази (p < 0,05). Встановлено сильний позитивний кореляційний зв’язок між β-AR activity та ступенем рубеозу райдужки за Weiss (rs=0,69; p<0,001). ROC-аналіз продемонстрував помірну дискримінаційну здатність β-AR activity щодо виявлення клінічно значущого рубеозу райдужки (Weiss ≥ 2) (AUC = 0,70). При пороговому значенні β-AR activity ≥ 14 ризик клінічно значущої неоваскуляризації райдужки зростав у 5,0 разів (OR = 5,02; 95% ДІ 2,64–9,56; p < 0,001).Висновки. Вторинна неоваскулярна глаукома асоціюється з підвищенням β-адренорецепторної активності, що може відображати залучення симпато-адреналової дисрегуляції до перебігу захворювання. Виявлений зв’язок між β-AR activity та вираженістю рубеозу райдужки свідчить про асоціацію системних нейровегетативних механізмів із клінічними проявами ангіогенної активності. β-AR може розглядатися як перспективний фенотип-визначальний маркер клінічної активності неоваскулярної глаукоми.
- Open Access
- 27 June 2026
- Published by Publishing House Zaslavsky in Archive of Ukrainian Ophthalmology
- Vol. 14 (2) , 98-109
Clinicopathogenetic phenotyping as the basis for a pathogenetically oriented personalized treatment system in secondary neovascular glaucoma
The purpose: to develop and validate clinicopathogenetic phenotyping as the basis for a pathogenetically oriented personalized treatment system in secondary neovascular glaucoma through the integration of clinical, laboratory, hemodynamic, and morphological parameters. Materials and methods. A prospective single-center cohort study included 224 patients (224 eyes) with secondary neovascular glaucoma caused by proliferative diabetic retinopathy (n = 133) or retinal vein occlusion (n = 91). The follow-up period was 36 months. Comprehensive ophthalmic, hemodynamic, and morphological examinations were performed, including assessment of systemic inflammatory indices (SII, SIRI, AISI), ICAM-1 (CD54), CD95, ocular microcirculation (RQ), and maximum ciliary body thickness. Principal component analysis was used to derive the Integrated Biological Activity Score (IBAS) as a composite measure of biological activity. Treatment burden was assessed using the Cumulative Burden Index. Results. Based on the integrated evaluation of clinical, laboratory, hemodynamic, and morphological parameters, four clinicopathogenetic phenotypes of secondary neovascular glaucoma were identified: compensated (31.7 %), ischemic-microcirculatory (30.8 %), inflammatory-endothelial (25.9 %), and proliferative-destructive (11.6 %). Principal component analysis confirmed the presence of a single integrated pathogenetic process (eigenvalue = 4.38; explained variance = 88.0 %). IBAS differed significantly among phenotypes (Kruskal-Wallis test: H = 129.81; p < 0.001). Clinicopathogenetic phenotypes also differed significantly in long-term treatment outcomes (χ² = 145.83; p < 0.001), risk of treatment failure (risk ratio = 35.50; 95 % confidence interval 9.08–138.74), and treatment burden, which increased progressively with phenotype severity. Based on these findings, a phenotype-oriented treatment algorithm was developed as a component of a pathogenetically oriented personalized treatment system for secondary neovascular glaucoma. Conclusions. The proposed clinicopathogenetic phenotyping system provides biologically and clinically meaningful stratification of patients with secondary neovascular glaucoma. IBAS quantitatively reflects the activity of the integrated pathogenetic process, whereas clinicopathogenetic phenotypes represent different levels of this activity, determine long-term prognosis, expected treatment burden, and serve as the basis for personalized selection of the sequence, intensity, and therapeutic goals of treatment.
- 27 June 2026
- Published by Publishing House Zaslavsky in Archive of Ukrainian Ophthalmology
- Vol. 14 (2) , 98-109
Open AccessClinicopathogenetic phenotyping as the basis for a pathogenetically oriented personalized treatment system in secondary neovascular glaucoma
The purpose: to develop and validate clinicopathogenetic phenotyping as the basis for a pathogenetically oriented personalized treatment system in secondary neovascular glaucoma through the integration of clinical, laboratory, hemodynamic, and morphological parameters. Materials and methods. A prospective single-center cohort study included 224 patients (224 eyes) with secondary neovascular glaucoma caused by proliferative diabetic retinopathy (n = 133) or retinal vein occlusion (n = 91). The follow-up period was 36 months. Comprehensive ophthalmic, hemodynamic, and morphological examinations were performed, including assessment of systemic inflammatory indices (SII, SIRI, AISI), ICAM-1 (CD54), CD95, ocular microcirculation (RQ), and maximum ciliary body thickness. Principal component analysis was used to derive the Integrated Biological Activity Score (IBAS) as a composite measure of biological activity. Treatment burden was assessed using the Cumulative Burden Index. Results. Based on the integrated evaluation of clinical, laboratory, hemodynamic, and morphological parameters, four clinicopathogenetic phenotypes of secondary neovascular glaucoma were identified: compensated (31.7 %), ischemic-microcirculatory (30.8 %), inflammatory-endothelial (25.9 %), and proliferative-destructive (11.6 %). Principal component analysis confirmed the presence of a single integrated pathogenetic process (eigenvalue = 4.38; explained variance = 88.0 %). IBAS differed significantly among phenotypes (Kruskal-Wallis test: H = 129.81; p < 0.001). Clinicopathogenetic phenotypes also differed significantly in long-term treatment outcomes (χ² = 145.83; p < 0.001), risk of treatment failure (risk ratio = 35.50; 95 % confidence interval 9.08–138.74), and treatment burden, which increased progressively with phenotype severity. Based on these findings, a phenotype-oriented treatment algorithm was developed as a component of a pathogenetically oriented personalized treatment system for secondary neovascular glaucoma. Conclusions. The proposed clinicopathogenetic phenotyping system provides biologically and clinically meaningful stratification of patients with secondary neovascular glaucoma. IBAS quantitatively reflects the activity of the integrated pathogenetic process, whereas clinicopathogenetic phenotypes represent different levels of this activity, determine long-term prognosis, expected treatment burden, and serve as the basis for personalized selection of the sequence, intensity, and therapeutic goals of treatment.
- Open Access
- 23 May 2026
- Published by Publishing House Zaslavsky in Archive of Ukrainian Ophthalmology
- Vol. 14 (1) , 12-19
Systemic inflammatory markers predict treatment outcomes in secondary neovascular glaucoma: a 24-month follow-up study
Background. Neovascular glaucoma remains one of the most aggressive forms of secondary glaucoma, and predicting treatment outcomes requires integration of clinical parameters with systemic biomarkers and advanced analytical approaches. The purpose was to evaluate the prognostic value of systemic inflammatory indices and endothelial activation markers (SII, SIRI, AISI, ICAM-1 (CD54)) for predicting treatment outcomes in secondary neovascular glaucoma at 24 months using multivariate statistical analysis and machine-learning approaches. Materials and methods. A retrospective analysis included 258 patients (258 eyes) with secondary neovascular glaucoma. The primary endpoint was the clinical treatment outcome at 24 months: clinical success group (achievement and maintenance of intraocular pressure < 22 mmHg without reduction in visual acuity) and group with ineffective treatment (failure). Systemic inflammatory indices (SII, SIRI, AISI) and the endothelial activation marker ICAM-1 (CD54) were assessed. Spearman correlation analysis, multivariate logistic regression, and machine-learning models (gradient boosting and multilayer perceptron) were applied. Results. Patients with treatment failure at 24 months demonstrated significantly higher baseline levels of SII, SIRI, AISI, and ICAM-1 (CD54) compared to the clinical success group, with a 1.3–2.2-fold increase (all p < 0.05). All systemic inflammatory indices and ICAM-1 (CD54) showed significant negative correlations with clinical treatment outcome (p < 0.05). Multivariate logistic regression and machine-learning models, based on systemic markers, provided moderate-to-high discriminative performance in predicting clinical success, with an area under the ROC curve of up to 0.83. SHAP analysis identified increased SIRI and AISI as the dominant negative contributors to treatment success probability. Conclusions. Systemic inflammation and endothelial activation markers in patients with secondary neovascular glaucoma have prognostic significance, are associated with long-term clinical treatment outcomes, and can be used for early risk stratification of treatment failure.
- 23 May 2026
- Published by Publishing House Zaslavsky in Archive of Ukrainian Ophthalmology
- Vol. 14 (1) , 12-19
Open AccessSystemic inflammatory markers predict treatment outcomes in secondary neovascular glaucoma: a 24-month follow-up study
Background. Neovascular glaucoma remains one of the most aggressive forms of secondary glaucoma, and predicting treatment outcomes requires integration of clinical parameters with systemic biomarkers and advanced analytical approaches. The purpose was to evaluate the prognostic value of systemic inflammatory indices and endothelial activation markers (SII, SIRI, AISI, ICAM-1 (CD54)) for predicting treatment outcomes in secondary neovascular glaucoma at 24 months using multivariate statistical analysis and machine-learning approaches. Materials and methods. A retrospective analysis included 258 patients (258 eyes) with secondary neovascular glaucoma. The primary endpoint was the clinical treatment outcome at 24 months: clinical success group (achievement and maintenance of intraocular pressure < 22 mmHg without reduction in visual acuity) and group with ineffective treatment (failure). Systemic inflammatory indices (SII, SIRI, AISI) and the endothelial activation marker ICAM-1 (CD54) were assessed. Spearman correlation analysis, multivariate logistic regression, and machine-learning models (gradient boosting and multilayer perceptron) were applied. Results. Patients with treatment failure at 24 months demonstrated significantly higher baseline levels of SII, SIRI, AISI, and ICAM-1 (CD54) compared to the clinical success group, with a 1.3–2.2-fold increase (all p < 0.05). All systemic inflammatory indices and ICAM-1 (CD54) showed significant negative correlations with clinical treatment outcome (p < 0.05). Multivariate logistic regression and machine-learning models, based on systemic markers, provided moderate-to-high discriminative performance in predicting clinical success, with an area under the ROC curve of up to 0.83. SHAP analysis identified increased SIRI and AISI as the dominant negative contributors to treatment success probability. Conclusions. Systemic inflammation and endothelial activation markers in patients with secondary neovascular glaucoma have prognostic significance, are associated with long-term clinical treatment outcomes, and can be used for early risk stratification of treatment failure.
- Open Access
- 22 May 2026
- Published by Medicines of Ukraine in Lìki Ukraïni
- No. 4(300),p. 17-24
Effectiveness of Combined Therapy with Citicoline (OMK-2) Electrophoresis in Patients with Ischemic Optic Neuropathy
Ischemic optic neuropathy is one of the causes of persistent visual impairment and is characterized by a combination of neurodegenerative and microvascular mechanisms of damage. The search for therapeutic approaches capable of enhancing the effectiveness of conservative treatment and providing more stable clinical outcomes remains clinically relevant. Purpose. To evaluate the effectiveness of combined treatment using citicoline electrophoresis (OMK-2) for 10 days followed by instillation of OMK-2 eye drops for 12 months, compared with standard drug therapy in patients with ischemic optic neuropathy. Materials and Methods. This prospective comparative study included 58 patients (58 eyes) with ischemic optic neuropathy of different etiologies. Patients were divided into two groups: Group 1 (n = 26) received standard therapy combined with a course of naso-orbital citicoline electrophoresis (10 procedures), followed by OMK-2 instillations for 12 months, whereas Group 2 (n = 32) received standard therapy alone. Best-corrected visual acuity (BCVA), peripapillary retinal nerve fiber layer thickness (RNFL), electrical sensitivity of the optic nerve measured by phosphene threshold (PhES), serum CD54 (ICAM-1), and HbA1c levels were evaluated at baseline and after 12 months. Data were analyzed using nonparametric statistical methods. Results. After 12 months, BCVA was significantly higher in the combined therapy group than in the standard treatment group (0.53 [0.30–0.60] vs 0.30 [0.17–0.30]; p = 0.018). The improvement in BCVA was also significantly greater in Group 1 (+0.33 [0.20–0.40]) compared with Group 2 (+0.10 [0.05–0.15]; p = 0.018). Group 1 demonstrated a more pronounced reduction in CD54 levels (p = 0.036), better structural outcomes reflected by RNFL thickness (p = 0.026), and more favorable changes in phosphene sensitivity (p = 0.048). The rate of clinically meaningful treatment response was nearly twice as high in the combined therapy group (88.5 % vs 50.0 %; p = 0.002). Conclusions. The addition of citicoline electrophoresis (OMK-2) and long-term OMK-2 instillations to standard therapy is associated with more pronounced and sustained improvement in visual function over 12 months and is accompanied by favorable changes in endothelial activation markers, as well as neurofunctional and structural parameters, including in patients with type 2 diabetes mellitus.
- 22 May 2026
- Published by Medicines of Ukraine in Lìki Ukraïni
- No. 4(300),p. 17-24
Open AccessEffectiveness of Combined Therapy with Citicoline (OMK-2) Electrophoresis in Patients with Ischemic Optic Neuropathy
Ischemic optic neuropathy is one of the causes of persistent visual impairment and is characterized by a combination of neurodegenerative and microvascular mechanisms of damage. The search for therapeutic approaches capable of enhancing the effectiveness of conservative treatment and providing more stable clinical outcomes remains clinically relevant. Purpose. To evaluate the effectiveness of combined treatment using citicoline electrophoresis (OMK-2) for 10 days followed by instillation of OMK-2 eye drops for 12 months, compared with standard drug therapy in patients with ischemic optic neuropathy. Materials and Methods. This prospective comparative study included 58 patients (58 eyes) with ischemic optic neuropathy of different etiologies. Patients were divided into two groups: Group 1 (n = 26) received standard therapy combined with a course of naso-orbital citicoline electrophoresis (10 procedures), followed by OMK-2 instillations for 12 months, whereas Group 2 (n = 32) received standard therapy alone. Best-corrected visual acuity (BCVA), peripapillary retinal nerve fiber layer thickness (RNFL), electrical sensitivity of the optic nerve measured by phosphene threshold (PhES), serum CD54 (ICAM-1), and HbA1c levels were evaluated at baseline and after 12 months. Data were analyzed using nonparametric statistical methods. Results. After 12 months, BCVA was significantly higher in the combined therapy group than in the standard treatment group (0.53 [0.30–0.60] vs 0.30 [0.17–0.30]; p = 0.018). The improvement in BCVA was also significantly greater in Group 1 (+0.33 [0.20–0.40]) compared with Group 2 (+0.10 [0.05–0.15]; p = 0.018). Group 1 demonstrated a more pronounced reduction in CD54 levels (p = 0.036), better structural outcomes reflected by RNFL thickness (p = 0.026), and more favorable changes in phosphene sensitivity (p = 0.048). The rate of clinically meaningful treatment response was nearly twice as high in the combined therapy group (88.5 % vs 50.0 %; p = 0.002). Conclusions. The addition of citicoline electrophoresis (OMK-2) and long-term OMK-2 instillations to standard therapy is associated with more pronounced and sustained improvement in visual function over 12 months and is accompanied by favorable changes in endothelial activation markers, as well as neurofunctional and structural parameters, including in patients with type 2 diabetes mellitus.
- 2 April 2026
- Published by National Ophthalmology Centre Named After Academician Zarifa Aliyeva in Azerbaijan Journal of Ophthalmology
- No. 2026/18/01
ARNOLD-CHIARI SYNDROME IN OPHTHALMOLOGY (CLINICAL CASES)
Arnold-Chiari syndrome is a pathology manifested by displacement of the cerebellum and cerebrum through the foramen of the spinal canal, inherited from the inconsistency of the dimensions of the posterior cranial fossa and placement brain structures. Purpose – to evaluate the results of a comprehensive approach to the differential diagnosis of Arnold-Chiari malformation in ophthalmology using two patients as an example. Materials and methods 2 patients (4 eyes) were examined for Arnold-Chiari malformation by generally accepted methods, and optical coherence tomography (OCT). Results There is no pathognomonic symptom or group of symptoms that allow for the clinical diagnosis of Arnold Chiari syndrome, and only neuroimaging diagnostics are possible. Whenever there is inflammation, congestive disc, or optic nerve atrophy, the first action of the ophthalmologist is to refer the patient for magnetic resonance imaging (MRI) or computed tomography (CT) imaging. Identification of relevant ophthalmological disorders at an early stage allows for timely suspicion and detection of this anomaly. Neuroimaging diagnostics justifies the doctor's alertness to this pathology. Conclusion Current diagnostic and treatment advances bring together specialists from various fields – ophthalmologists, radiologists, and neurologists – and present new challenges for physicians. The presented series of clinical cases demonstrated possible manifestations of Arnold-Chiari syndrome, including strabismus and congestion in the optic nerve, which was confirmed by MRI. Key words: Arnold-Chiari syndrome, optical coherence tomography, optic nerve, magnetic resonance imaging
- 2 April 2026
- Published by National Ophthalmology Centre Named After Academician Zarifa Aliyeva in Azerbaijan Journal of Ophthalmology
- No. 2026/18/01
ARNOLD-CHIARI SYNDROME IN OPHTHALMOLOGY (CLINICAL CASES)
Arnold-Chiari syndrome is a pathology manifested by displacement of the cerebellum and cerebrum through the foramen of the spinal canal, inherited from the inconsistency of the dimensions of the posterior cranial fossa and placement brain structures. Purpose – to evaluate the results of a comprehensive approach to the differential diagnosis of Arnold-Chiari malformation in ophthalmology using two patients as an example. Materials and methods 2 patients (4 eyes) were examined for Arnold-Chiari malformation by generally accepted methods, and optical coherence tomography (OCT). Results There is no pathognomonic symptom or group of symptoms that allow for the clinical diagnosis of Arnold Chiari syndrome, and only neuroimaging diagnostics are possible. Whenever there is inflammation, congestive disc, or optic nerve atrophy, the first action of the ophthalmologist is to refer the patient for magnetic resonance imaging (MRI) or computed tomography (CT) imaging. Identification of relevant ophthalmological disorders at an early stage allows for timely suspicion and detection of this anomaly. Neuroimaging diagnostics justifies the doctor's alertness to this pathology. Conclusion Current diagnostic and treatment advances bring together specialists from various fields – ophthalmologists, radiologists, and neurologists – and present new challenges for physicians. The presented series of clinical cases demonstrated possible manifestations of Arnold-Chiari syndrome, including strabismus and congestion in the optic nerve, which was confirmed by MRI. Key words: Arnold-Chiari syndrome, optical coherence tomography, optic nerve, magnetic resonance imaging